Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
BCX.WA
Strong SellSinkerBioceltix S.A. · Healthcare · Poland · $118M · Avg Vol: $199K/d
COMPANY DESCRIPTION
Bioceltix S.A. is a biotechnology company developing veterinary biopharmaceuticals, specifically stem cell-based therapies for companion animals. The company's competitive moat is its proprietary technology platform for manufacturing allogeneic stem cells and its advanced regulatory pathway toward European marketing authorization. It is a pioneering niche player in the rapidly growing veterinary biotech sector.
FINANCIAL SUMMARY (PLN)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | — | 15.3M | — |
| EPS (PLN) | -2.67 | -3.49 | -3.20 | -3.03 | — | -3.29 | -2.00 | -1.90 | — |
| Shares | 3.4M | 4.1M | 4.9M | 5.5M | +61.4% | 5.5M | — | — | — |
| Debt | 0.3M | 0.2M | 0.8M | 0.3M | 2.3% | 0.2M | — | — | — |
| Equity | 5.2M | 10.5M | 38.8M | 73.3M | 142.3% | — | — | — | — |
| Op CF | -7.9M | -14.7M | -17.6M | -11.9M | — | -17.6M | — | — | — |
| Inv CF | -0.4M | -0.5M | -84.2K | -2.0M | — | — | — | — | — |
| Fin CF | 6.3M | 20.4M | 42.0M | 48.7M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of BCX.WA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| BCX.WA | Bioceltix S.A.(you) | $118M | 18 | Strong Sell |
| CTX.WA | Captor Therapeutics Spolka Akcyjna | $120M | 6 | Strong Sell |
| RVU.WA | Ryvu Therapeutics S.A. | $113M | 4 | Strong Sell |
| S2B.WA | Syn2bio S.A. | $148M | 3 | Strong Sell |
| SVE.WA | Synthaverse S.A. | $46M | 11 | Strong Sell |
| MOC.WA | Molecure S.A. | $40M | 14 | Strong Sell |
| PTG.WA | Poltreg S.A. | $34M | 13 | Strong Sell |
| NNG.WA | NanoGroup S.A. | $28M | 14 | Strong Sell |
| MAB.WA | Mabion S.A. | $34M | 10 | Strong Sell |
| BIO.WA | BIOTON S.A. | $87M | 51 | Hold |
Peer medians: ROE -16.3% · P/E 17.0x · Gross margin 32.5%